Biogen IDEC Inc. (BIIB-Q)

https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

He Prefers VRTX-Q. You need to invest in the most innovative companies in this sector.

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.